ABSTRACT
RELEVANCE. Neurological diseases are a global health and social issue caused by increasing proportion of оlder people, especially in developed countries, and the incidence of neurodegenerative diseases. Among the promising therapeutic approaches, metabolic agents are receiving particular attention.

AIM. To conduct an analytical review of current literature on the effects of acetyl-L-carnitine on neurological diseases.

MATERIALS AND METHODS. A meticulous analysis of systematic reviews, meta-analyses, and randomized clinical trials indexed in the eLibrary, Cochrane Library, PubMed, and MEDLINE databases was performed.

RESULTS AND DISCUSSION. Acetyl-L-carnitine (ALC) is the main acetyl ester of L-carnitine. It improves mitochondrial metabolism and has neuroprotective, neurotrophic, antidepressant, and analgesic effects. Our results have shown that ALC is an effective approach in treating various neurological diseases and preventing of their complications.

CONCLUSION. ALC is a promising agent in the treatment of early cognitive decline, diabetic peripheral neuropathy and amyotrophic lateral sclerosis.

KEYWORDS: аcetyl-L-carnitine, neurodegenerative diseases, cognitive impairment, neuropathies, hepatic encephalopathy 

For citation: Borisova A.V. Effectiveness of Acetyl-L-сarnitine in Patients with Neurological Diseases: А Review of Current Data. Comorbidity Neurology. 2026; 3 (2): 75–81. https://doi.org/10.62505/3034-185x-2026-3-2-75-81

For correspondence: Anna V. Borisova, Ph.D. Med. (Sci.), Associate Professor, Department of Obstetrics and Gynecology with the Course of Perinatology, Medical Institute, Peoples' Friendship University of Russia named after Patrice Lumumba, e-mail: borisova_av@rudn.ru.

REFERENCES

1. Dattani S., Spooner F., Ritchie H., Roser M. Causes of Death. Published online at ourworldindata.org. 2023. https://ourworldindata.org/causesof-death [Online Resource]. 

2. World Health Organization. Global status report on neurology. 2025: 285

3. Dias-Carvalho A., Sá S.I., Carvalho F., et al. Inflammation as common link to progressive neurological diseases. Arch. Toxicol. 2024; 98 (1): 95–119. https://doi.org/10.1007/s00204-023-03628-8

4. Zhang G., Wei H., Zhao A., et al. Mitochondrial DNA leakage: underlying mechanisms and therapeutic implications in neurological disorders. J. Neuroinflammation. 2025; 22 (1): 34. https://doi.org/10.1186/s12974-025-03363-0

5. Li Y., Zhang W., Zhang Q. et al. Oxidative stress of mitophagy in neurodegenerative diseases: Mechanism and potential therapeutic targets. Arch. Biochem. Biophys. 2025; 764: 110283. https://doi.org/10.1016/j.abb.2024.110283

6. Teleanu R.I., Niculescu A.G., Roza E. et al. Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. Int. J. Mol. Sci. 2022 May 25; 23 (11): 5954. https://doi.org/10.3390/ijms23115954

7. Traina G. The neurobiology of acetyl-L-carnitine. Front Biosci (Landmark Ed). 2016; 21 (7): 1314–29. https://doi.org/10.2741/4459

8. White H.L., Scates P.W. Acetyl-l-Carnitine as a Precursor of Acetylcholine. Neurochemical Research. 1990; (6 ): 597–601. https://doi.org/10.1007/BF00973749

9. Pochini L., Galluccio M., Scalise M., et al. OCTN: A Small Transporter Subfamily With Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics, SLAS Discovery. 2019; 2: 89–110. https://doi.org/10.1177/2472555218812821

10. Pettegrew J.W., Levine J., McClure R.J. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol. Psychiatry. 2000; 5: 616–632.

11. Abdul H., Butterfield D. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and a-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: Implications for Alzheimer’s disease. Free Radical Biol. Med. 2007; 42 (3): 371–384.

12. Virmani A., Pinto L., Bauermann O., et al. The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions. Molecular Neurobiology. 2015; 2: 826–836. https://doi.org/10.1007/s12035-015-9238-7

13. Anikin G.S., Makhova A.A., Shikh E.V. Prospects of application of acetyl-L-carnitine in neurology and psychiatry (the treatment of polyneuropathy and depressive states). S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119 (8): 130–135. https://doi.org/10.17116/jnevro2019119081130 (In Russ.)

14. Руководство по гериатрической психиатрии. Под ред. Гавриловой С.И. М.: МЕДпресс-информ. 2020; 440.

15. Sepand M.R., Razavi-Azarkhiavi K., Omidi A. et al. Effect of Acetyl-L-Carnitine on Antioxidant Status, Lipid Peroxidation, and Oxidative Damage of Arsenic in Rat. Biol Trace Elem Res. 2016 May; 171 (1): 107–115. https://doi.org/10.1007/s12011-015-0436-y

16. Mazdeh M., Abolfathi P., Sabetghadam M. et al. Clinical Evidence of Acetyl-L-Carnitine Efficacy in the Treatment of Acute Ischemic Stroke: A Pilot Clinical Trial. Oxid Med Cell Longev. 2022: 2493053. https://doi.org/10.1155/2022/2493053

17. Palacios H.H., Yendluri B.B., Parvathaneni K. et al. Mitochondrionspecific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets. 2011; 10 (2): 149–162. https://doi.org/10.2174/187152711794480474

18. Ponomareva E.V. Use of acetyl-L-carnitine in gerontological practice. S.S. Korsakov Journal of Neurology and Psychiatry. Special issues 2017; 117 (6–2): 81–86. (In Russ.)

19. Nasca C., Xenos D., Barone Y. et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc. Natl. Acad. Sci. USA. 2013; 110: 4804–4809. https://doi.org/10.1073/pnas.1216100110

20. Chiechio S., Canonico P.L., Grilli M. L-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug. Int J Mol Sci. 2017; 19 (1): 11. https://doi.org/10.3390/ijms19010011

21. Smeland O.B., Meisingset T.W., Borges K. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochemical Int. 2012; 61 (1): 100–107. https://doi.org/10.1016/j.neuint.2012.04.008

22. Montgomery S., Thal L., Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol. 2003; 18 (2): 61–71.

23. Gavrilova S.I., Kalyn Ya.B., Kolykhalov I.V., Roshchina I.F., Selezneva N.D. Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2011; 111 (9): 16–22. (In Russ.)

24. Fedorova Ya.B., Kolykhalov I.V., Gavrilova S.I. Experience of clinical use of acetyl-L-carnitine (Carnicetin) in patients with amnestic type of mild cognitive decline syndrome. Consilium medicum. Neurology. 2014; 1: 60–65. (In Russ.)

25. Malaguarnera G., Catania V.E., Bertino G. et al. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial. Curr Pharm Des. 2022; 28 (38): 3158–3166. https://doi.org/10.2174/1381612828666220830092815

26. Grossini E., De Marchi F., Venkatesan S. et al. Effects of Acetyl-L-Carnitine on Oxidative Stress in Amyotrophic Lateral Sclerosis Patients: Evaluation on Plasma Markers and Members of the Neurovascular Unit. Antioxidants (Basel). 2023; 12 (10): 1887. https://doi.org/10.3390/antiox12101887

27. McAlary L., Plotkin S.S., Yerbury J.J., Cashman N.R. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci 2019; 12: 262. http://doi.org/10.3389/fnmol.2019.00262

28. Beghi E., Pupillo E., Bonito V. et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14 (5–6): 397–405. https://doi.org/10.3109/21678421.2013.764568

29. Sassi S., Bianchi E., Diamanti L. et al. Retrospective observational study on the use of acetyl-L-carnitine in ALS. J. Neurol. 2023; 270 (11): 5344–5357. https://doi.org/10.1007/s00415-023-11844-6

30. Jin R., Liu L., Zhang S. et al. Role of inflammation and its mediators in acute ischemic stroke. Journal of Cardiovascular Translational Research. 2013; 6 (5): 834–851. https://doi.org/10.1007/s12265-013-9508-6.

31. Zhang R., Zhang H., Zhang Z. et al. Neuroprotective effects of pre-treatment with L-carnitine and acetyl-L-carnitine on ischemic injury in vivo and in vitro. Int J Mol Sci. 2012; 13 (2): 2078–2090. https://doi.org/10.3390/ijms13022078

32. Sergi G., Pizzato S., Piovesan F., Trevisan C., Veronese N., Manzato E. Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders. Aging Clin Exp Res. 2018; 30 (2): 133–138. https://doi.org/10.1007/s40520-017-0770-3

33. Sima A.A.F., Munish Mehra M.C., Amato A. Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care. 2005; 28 (1): 89–94. https://doi.org/10.2337/diacare.28.1.89

34. Li S., Chen X., Li Q. et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016 Sep; 7 (5): 777–785. https://doi.org/10.1111/jdi.12493

35. Sun Y., Shu Y., Liu B., et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapyinduced peripheral neuropathy. Exp Ther Med. 2016; 12 (6): 4017–4024. https://doi.org/10.3892/etm.2016.3871

36. Haynes J., Joshi A., Larue RC. et al. Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport. Pharmaceutics. 2024 Dec 13; 16 (12): 1592. https://doi.org/10.3390/pharmaceutics16121592

37. Hart A.M., Wilson A.D., Montovani C. et al. Acetyl-l-carnitine: a pathogenesis-based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004; 18 (11): 1549–1560. https://doi.org/10.1097/01.aids.0000131354.14408.fb

38. Osio M., Muscia F., Zampini L. et al. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients : an open label study. J Peripher Nerv Syst. 2006; 11 (1): 72–76. https://doi.org/10.1111/j.1085-9489.2006.00066.x

39. Youle M., Osio M., ALCAR Study Group. A double-blind, parallel group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007; 8 (4): 241–250. https://doi.org/10.1111/j.1468-1293.2007.00467.x

40. Fernández-de-Las-Peñas C., Fuensalida-Novo S., Nijs J.et al. Carpal Tunnel Syndrome: Neuropathic Pain Associated or Not with a Nociplastic Condition. Biomedicines. 2023; 11 (6): 1744. https://doi.org/10.3390/biomedicines11061744

41. Cruccu G., Di Stefano G., Fattapposta F. et al. L-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain. CNS Drugs. 2017; 31 (12): 1103–1111. https://doi.org/10.1007/s40263-017-0476-2

ADDITIONAL INFORMATION

Anna V. Borisova, Ph.D. Med. (Sci.), Associate Professor, Department of Obstetrics and Gynecology with the Course of Perinatology, Medical Institute, Peoples' Friendship University of Russia named after Patrice Lumumba. E-mail: borisova_av@rudn.ru. ORCID: https://orcid.org/0000-0003-4716-2886

Author contributions. Author confirm the compliance of their authorship, according to international ICMJE criteria (conducting research and preparing an article).

Funding. This study was supported by external sources of funding.

Disclosure. The material was prepared with the support of MRM Nutrition.

The content is available under the Creative Commons Attribution 4.0 License.

©2026. Anna V. Borisova